Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV golimumab induction in moderately to severely active ulcerative colitis (Phase 2/3, Part 1 dose-ranging)
2006-003397-94Phase 2Terminated
- Sponsor
- Janssen Biotech
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing IV golimumab induction with Placebo IV induction (2 arms). Primary endpoint: Clinical remission at induction endpoint (Part 1, dose-ranging). Started Jul 2007; status: terminated.
02
Drugs
golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2006-003397-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003397-94.